Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection

Inclusion Criteria: 1. \- Subjects who voluntarily sign informed consent forms 2. \- Both genders. 3. \- Subjects aged between 18 and 70 years. 4. -Subjects capable of complying with the treatment 5. \- Subjects admitted to hospital with non-severe pneumonia (CURB-65≤2) by COVID-19 6. \- Confirmatory test for COVID-19 infection Exclusion Criteria: 1. \- Subjects who has not signed informed consent forms 2. \- Subjects included in another clinical trial. 3. \- Subjects under treatment with immunosuppressants. 4. \- Subjects in treatment with another type of immunotherapy. 5. \- Subjects who are or have been undergoing treatment with metformin. 6. \- Subjects who are or have been treated with statins. 7. \- Subjects who are or have been under treatment with sertraline. 8. \- Pregnant women. 9. \- Subjects who cannot offer cooperation and / or have serious psychiatric disorders. 10. -Subjects who are allergic to any of the components of BACTEK-R (MV130). 11. \- Subjects with pathologies described in the Charlson index